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Abstract
There is an urgent need for new anti-malaria drugs with broad therapeutic potential and novel mode of action, for
effective treatment and to overcome emerging drug resistance. Plant-derived anti-malarials remain a significant
source of bioactive molecules in this regard.
The multicomponent formulation forms the basis of phytotherapy. Mechanistic reasons for the poly-pharmacological
effects of plants constitute increased bioavailability, interference with cellular transport processes, activation of
pro-drugs/deactivation of active compounds to inactive metabolites and action of synergistic partners at different
points of the same signaling cascade. These effects are known as the multi-target concept. However, due to the
intrinsic complexity of natural products-based drug discovery, there is need to rethink the approaches toward
understanding their therapeutic effect.
This review discusses the multi-target phytotherapeutic concept and its application in biomarker identification using
the modified reverse pharmacology - systems biology approach. Considerations include the generation of a product
library, high throughput screening (HTS) techniques for efficacy and interaction assessment, High Performance Liquid
Chromatography (HPLC)-based anti-malarial profiling and animal pharmacology. This approach is an integrated
interdisciplinary implementation of tailored technology platforms coupled to miniaturized biological assays, to track
and characterize the multi-target bioactive components of botanicals as well as identify potential biomarkers. While
preserving biodiversity, this will serve as a primary step towards the development of standardized phytomedicines, as
well as facilitate lead discovery for chemical prioritization and downstream clinical development.
Keywords: Malaria, Phytotherapy, Multi-target effects, Reverse pharmacology, High throughput screening (HTS),
HPLC-based anti-malarial profiling, In vivo pharmacology, Pharmacokinetics
Background
Malaria control initiatives have led to substantial im-
provement in the number of saved lives in vulnerable
populations, particularly in those with access to effect-
ive anti-malarial drugs [1]. In spite of this, Plasmodium
falciparum malaria remains a major public health bur-
den in most endemic countries, where there is lack of
access to modern healthcare facilities and disease moni-
toring is not well defined. Most of the populations in
these countries resort to the use of plant-based comple-
mentary medicine for therapy [2]. Drugs derived from
natural source, especially herbs, represent a significant
proportion of the pharmaceutical market, particularly
in malaria therapy, as well as other infectious diseases.
Examples include quinine from Cinchona species, arte-
misinin from Artemisia annua and atovaquone from
Tabebuia impetiginosa [3, 4]. Their advantage for the
development of drugs comes from the synergistic interac-
tions of their components and their innate affinity for bio-
logical receptors [5]. The pharmacological justification of
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these principles could provide the basis for further devel-
opment of plant-based traditional medicine as a reliable
therapeutic tool.
Malaria parasite has developed resistance to many of
the currently available drugs, including emerging resist-
ance to the core artemisinin component of the
artemisinin-based combination (ACT) therapies [6].
This therefore underscores the need to explore new
therapeutic strategies from natural products. Although
the physiopathology of malaria is not fully understood,
the knowledge that its pathogenesis involves multiple
factors, obliges effective therapeutic approaches to shift
from the conventional “one target, one drug” to a new
“multi-target, multidrug” model [7, 8]. The require-
ments for the development of new anti-malarials to
support the current therapeutic and eradication agenda
include novel modes of action with no cross resistance
to current drugs, multiple-stage efficacy and anti-
relapsing activity [9].
Herbal medicines are preparations that contain plant
parts (singly or in combination) in a pharmaceutically
processed form. Like synthetic drugs, they claim thera-
peutic or prophylactic properties and may exhibit
poly-pharmacological effects through interactions of
their constituent phytochemicals. Assumed mechanis-
tic reasons for these interactions include increased
bioavailability, interference with cellular transport pro-
cesses, activation of pro-drugs/deactivation of active
compounds to inactive metabolites and action of syn-
ergistic partners at different points of the same signal-
ing cascade. This concept is known as the multi-target
effect [7]. The application of this concept in drug dis-
covery requires the comprehensive characterization of
the constituent phytochemicals and their bioactivities.
The multicomponent therapy forms the basis of phy-
totherapy or phytomedicines, where holistic thera-
peutic effect result from complex positive and negative
interactions between the different components [10].
However, these bioactive components, known as me-
tabolites possess high chemo-diversity and constitute
the complex biological matrices of these plants. A
knowledge of their pharmacological activities is neces-
sary to understand the basis of their therapeutic effect
and this necessitates broad interdisciplinary research
approaches [11, 12]. Therefore, more than one bio-
logical test system is required to measure the thera-
peutically useful activities, in an attempt to establish
consistency in herbal drugs. Moreover, the application
of appropriate technology and bioassays is imperative
in the application of this concept.
In the search for new lead compounds from natural
source in malaria drug discovery, the efficient tracking
and early identification of active constituents in complex
matrices remains the most challenging step due to the
chemical properties of plant extracts and the mechanism
of their bioactivity [13]. However, the conventional
bioactivity-guided isolation involving several iterative
steps is first and foremost inefficient and time consum-
ing, especially when the bioactive phytochemical is an
unknown compound and exists as a minor component
in the extract. Secondly, if bioactivities of plant extracts
are as a result of the synergistic effects of phytochemi-
cals, testing pure phytochemicals in bioassays might not
be able to fully reveal their bioactivities. Finally, it re-
quires large amounts of material, thereby destabilizing
biodiversity. Though successful in the past, this classical
approach relied on several iterative steps which brought
about repeated isolation of the same compounds and it
could not keep pace with the fast turn around and tight
deadline of high throughput screening (HTS)-based pro-
grammes [14]. Moreover, in vitro efficacy assays for
these bioactive compounds are usually target-driven and
do not allow the detection of truly novel targets or iden-
tification of the complex summary effects due to the in-
teractions of different constituents. This has brought
about renewed interests in holistic in vivo test systems,
which are more suitable to unravel synergism or identify
pro-drugs which are converted metabolically to bioactive
substances. To tackle these challenges, new research
strategies employ tools such as metabolomics, a key in
systems biology, for the diversity-oriented screening of
herbal medicines. Besides, the normal pharmacological
read-outs in malaria infection such as multiple-stage-
antiplasmodial, anti-inflammatory, antipyretic, antioxi-
dant and antinociceptive effects, there is the possibility
of correlating these measurements in a system biological
approach with analyzed metabolomics data [15, 16].
Metabolomics, is a key “omics” technology in systems
biology. It is the comprehensive qualitative and quanti-
tative analysis of the bioactive molecules in a cell, organ
or organism at a specific point in time. It is a highly
versatile strategy to accelerate deconvolution of active
extracts, in which a variety of detection methods are
adopted for metabolite analysis including electrochem-
ical array, infrared spectroscopy, mass spectrometry
(MS) and nuclear magnetic resonance (NMR). Amongst
the available platforms, the hyphenation of HPLC-MS,
coupled to NMR spectroscopy is the most widely used
technology due to its ability to detect and separate a di-
verse range of molecules with high sensitivity [17].
Summarily, after subjecting chosen plants through
the standardized extraction procedures, preliminary
pharmacological assays are carried out to determine
their efficacy and safety. Subject to this, the plant tissue
will be subjected to derivatization and untargeted
metabolomics-based phytochemical profiling. Eluted
fractions will be used for relevant in vitro bioassay ac-
tivities, such as multiple-parasite-stage-antiplasmodial,
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antioxidant, anti-inflammatory, antipyretic and antino-
ciceptive activities. Acquired ultraviolet (UV) and MS
data will be used for dereplication and tentative identi-
fication of known compounds, as well as to pinpoint
potentially new compounds. The chromatogram and
the activity profile will then be matched to identify ac-
tive peaks. Characterization will be done by analyzing
the NMR data for eluted fractions or peaks recorded
off-line using microprobe technology. Metabolomics-
based phytochemical profiling and in vitro bioassays
may establish the correlation between specific phytochem-
icals and different bioactivities leading to the identification
of biomarkers. Synergistic multi-target biomarkers are
expected to be identified and used for in vivo valid-
ation. This data could also be used in targeted metabo-
lomics analysis, for lead identification and eventual
downstream chemical production analyses and clinical
development (Fig. 1).
Although there are some standardized anti-malarial
phytomedicines in current use in some endemic coun-
tries [18], the continuous and unsafe use of non-
standardized plant-derived products in many malaria
endemic countries obliges new approaches.
Herewith an overview of the emerging methodological
landscape in the application of the multi-target phy-
totherapeutic concept in malaria drug discovery. This
interdisciplinary approach employs tailored technology
platforms coupled to miniaturized biological assays to
track and characterize the anti-malarial components of
herbal medicines.
By combining the modified reverse pharmacology to
the systems biology approaches, the bioactivities of dif-
ferent phytochemicals can be assessed, in view of the
identification of potential biomarkers. This will facilitate
unravelling of the multi-target phytotherapeutic mecha-
nisms and the standardization of herbal medicines as
well as facilitate lead discovery for prioritization and
downstream clinical analyses. Therefore, its application in
malaria drug discovery could be of immense importance.
Generation of a plant extract/compound library
A library can be defined as a collection of plant extracts/
compounds stored in a standardized format and readily
deliverable for screening assays. The information associ-
ated with each sample is usually stored in a database.
Prior to establishing an extract library, key issues that
have to be considered include the choice of plants and
suitable extraction procedures to be applied to the
samples.
Choice of plants
The choice of plants as test material remains the most chal-
lenging and a determinant factor in plant-based malaria
drug discovery process. There are various approaches to se-
lect plant material for this process and these include the
A B
Fig. 1 Work flow for the application of metabolomics in analysis of HMs. a HPLC-based activity profiling. b Phytochemical profiling (untargeted
metabolomics) Metabolomics-based phytochemical profiling and in vitro bioassays of bioactivities may establish the correlation between specific
phytochemicals and different bioactivities leading to the identification of biomarkers
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random selection, ethnopharmacological, chemosystematic
(phylogenetic), ecological and computational approaches.
The random selection of extracts and/or fractions
from different plant species on the basis of their avail-
ability can be highly advantageous when samples are
derived from areas of high biodiversity and malaria en-
demism [19]. This is because the chemical diversity of
natural products can reflect the biodiversity of their
source organism. Random selection of plant material
can potentially result in the unexpected identification
of bioactivities that would not be predicted based on
indigenous or existing knowledge [20].
Ethnopharmacology is the classical approach for the
choice of plants for bioassays and involves the gathering
of data on the indigenous use of the plants as a basis for
their selection. This usually involves the observation, de-
scription, and experimental assessment of traditionally
used medicines and their effects on humans. It repre-
sents a transdisciplinary concept between the natural
(botany, chemistry, biochemistry, pharmacology and
pharmacognosy) and the social sciences (anthropology,
archeology, history and linguistics) [12, 21]. This ap-
proach has led to the prominent discovery of some vital
anti-malarials. Examples include the isolation of quinine
from Cinchona species 1820 and its derivatives, chloro-
quine and mefloquine which replaced it in the 20th
century [22]. Artemisinin was isolated from Artemisa
annua in 1971 and constitutes the core of artemisinin-
based combination therapies (ACT) and its derivatives,
artesunate and artemether which are widely in use cur-
rently [23]. A recently introduced plant-derived antimal-
arial drug is atovaquone, a synthetic naphthoquinone
based on lapachol, a prenylnaphtoquinone, first isolated
from Tabebuia impetiginosa, a South American member
of the Bignoniaceae family [4]. Ethnopharmacological
data is easily accessible in well-established traditional
health systems such as the Traditional Chinese Medicine
(TCM) and Ayurveda, which possess current docu-
mented evidence of centuries. However, this is not the
case with other health systems such as the African
Traditional health system, where knowledge is passed
on from one generation to the other orally, and formu-
lations in use are usually kept secret by the aging prac-
titioners, rendering access to relevant information
difficult [21, 24]. Hence, depending on the plant to be
studied, there are various sources of acquiring information
such as books on medical botany, review articles on medi-
cinal plants used in different geographical regions or cul-
tures [25] as well as computer databases [26].
The chemosystematic or phylogenetic approach is
based on the chemotaxonomy and phylogeny taking into
account that plant species from some genera or families
are known to produce compounds and compound clas-
ses associated with a certain bioactivity or therapeutic
potential [20]. The combination of phylogenetic infor-
mation and ethnobotanical knowledge can be a very
powerful tool in natural product drug discovery. The ex-
ploration of cross-cultural ethnomedical patterns within
a phylogenetic framework can lead to high success rates
[27, 28].
The ecological approach is based on the observation
of interactions between organisms and their environ-
ment, considering that plant secondary metabolites
possess ecological functions from which a potential
therapeutic use for humans can be derived [20]. For ex-
ample, compounds with antimalarial activity could be
isolated from plant species eaten by chimpanzees and
baboons in the wild [29].
The computational approach relies on in silico bio-
activity predictions for constituents of certain plant spe-
cies. These studies can focus on the main constituents of
herbal remedies as well as on other natural compounds
with anti-malarial effects directly retrieved from litera-
ture [30].
Having appropriately identified and sourced the
plant(s) of choice, the next step in the value addition of
medicinal plants bio-resources is the production of
herbal preparations (extracts) using a variety of tech-
nologies from simple traditional technologies to advance
extraction techniques, subject to the choice of assay.
Extraction procedure
Extraction is the separation of medicinally active compo-
nents (secondary metabolites) of plant tissues, using
relevant solvents and standard conditions. A key aspect
to the characterization of plant-derived active compo-
nents is the selection of an adapted extraction protocol
that would be suitable for the detection of the bio-
markers of interest. This is a fundamental and critical
step with important consequences for the accuracy of
outcomes [31]. To increase extraction yields, plants are
typically ground to a fine powder. However, when fresh
material is used, it is imperative for the grinding process
to be done on ice.
The aim of characterizing the bioactive components in
plants is to comprehensively profile the largest possible
array of low molecular weight metabolites in a given
sample. In order for this to be achieved, extraction pro-
cedures with solvents that can extract compounds over a
broad polarity range need to be utilized. And since there
is no single solvent that has the ability to extract and dis-
solve all the plant metabolites at once, several solvents of
increasing polarity need to be used in succession, such as
hexane > ethylacetate >methanol > ethanol > water. This is
the classical approach used for phytochemical screening
and bio-activity guided fractionation, and it is difficult to
implement in modern characterization studies known
as metabolomics, because it generates many different
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extracts per sample that have to be analyzed separately,
which usually is not compatible with the large number
of samples that need to be analyzed. A dependable al-
ternative is a combination of various solvents, such as a
multi-phase solvent system composed of a mixture of
solvents, such as chloroform-methanol—water, which
has been proposed for such studies which are per-
formed with pure methanol or a mixture containing it
[31]. In this regard, there are various parameters to be
considered in the solvent systems to be utilized,
which should make it compatible with the applicable
analytical technique. These include the nature of the
organic and aqueous solvents, the volumes, ratios
and aqueous solvent pH. For example, an aspect that
needs to be considered is that lipophilic compounds
do not elute from C18 reversed phase columns and
certain methanol—water mixtures do not extract
chlorophyll from plant aerial parts, which might be
an advantage for incorporating LC analysis in
MS—based metabolomics [13].
To accelerate the extraction process, additional energy
needs to be applied to reduce the extraction time. This
can be achieved by directly heating the system and in-
creasing the pressure by using techniques such as the
microwave-assisted extraction, supercritical fluid extrac-
tion and the mostly used pressurized (or accelerated)
solvent extraction [32, 33]. These enable an efficient ex-
traction under standardized conditions and make use of
very little quantities of the plant material to be extracted,
which are compatible with miniaturization of assays and
the generalization of the microplate format. Moreover,
extraction temperatures are usually maintained below
the solvent boiling points for yield optimization and
preservation of metabolite chemistry.
A review of potential anti-malarial components that
have been identified from plants cover a very wide range
of phytochemicals classes, which include alkaloids, ter-
penoids, flavonoids, coumarins, phenolics, polyacety-
lenes, xanthones, quinones, steroids and lignans [3, 34,
35]. Extracting each necessitates specific extraction tech-
nique, making it cumbersome and time-consuming for
the investigator, especially given the fact that there
might be little or no activity after extraction and isola-
tion, as has been the case with many small molecules
that have been tested for their activity. Since this
reverse pharmacology – systems biology approach
entails a farm - to-clinic process, whereby the ethno-
pharmacological knowledge and pharmacological val-
idation is vital before HPLC-based anti-malarial
profiling, solvent extracts will be dried are stored in a
standardized (usually microplate) format, readily avail-
able for screening assays, biomarker and target identi-
fication, while the information associated with each
sample are stored in a database.
Choice of bioassays in in vitro efficacy and safety
In malaria drug discovery, efficacy and safety screening
is a long and costly process confronted with low prod-
uctivity, thereby limiting the number of new drugs. In
order to improve on this, recent efforts have been dedi-
cated to developing high throughput screening (HTS)
platforms that mimic in vivo systems and provide more
relevant information than biochemical assays, for the
pipeline [36]. For the purposes of screening natural
products, cell-based HTS methods are more relevant
and typically make use of 96, 384 and 1536-well (in au-
tomated systems) microtitre plates and can be per-
formed in a more biological relevant microenvironment.
The main components are cells or parasites, culture de-
vice and detection system for quantification of cells or
bioactivities. When used in screening plant extracts and
other drugs, they provide representative tissue specific
responses, which can be useful in efficacy and safety
screening, biomarker and target identification, thereby
facilitating standardization.
In vitro antiplasmodial efficacy
In vitro screening of malaria parasite laboratory strains
and field isolates for susceptibility against test com-
pounds provides an early indication of drug efficacy,
failure or possible clinical resistance. These screens
are usually whole-cell based and require screening
both the erythrocyte and exo-erythrocytic stages [37].
They serve first and foremost to identify active ex-
tracts before subjecting them to metabolomics analysis
and secondly for the identification of potential bio-
markers after metabolomics characterization of their
phytochemical constituents.
In the erythrocyte stage screening, inhibition is mon-
itored by measures of growth and proliferation of P.
falciparum strains, usually without knowledge of the
molecular targets of the compounds that are being
screened [38]. HTS methods currently being used to
measure P. falciparum in vitro drug susceptibility in-
clude the 3H-hypoxanthine incorporation assay [39],
histidine-rich protein-2 enzyme linked immunosorbent
assay (HRP-2 ELISA) [40, 41], parasite lactate dehydro-
genase colorimetric assay (pLDH) [42] and the most
recent SYBR Green-1 fluorescence assay [43, 44]. The
titriated hypoxanthine uptake assay involves measuring
parasite growth by recording levels of titriated hypo-
xanthine incorporation into the parasite DNA. Though
accurate and reliable, its major shortcoming is the use
of radioactivity, the safe disposal of which demands
substantial resources. The HRP-2 method assesses para-
site growth by using ELISA to measure P. falciparum
HRP-2 and offers better result upon examining drug
susceptibilities of field isolates using non-radioactive
procedure. It is also more cost effective compared to
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the 3H-hypoxathine method. The pLDH assay is an
indirect method that measures P. falciparum LDH ac-
tivity as an assessment of parasitaemia by colorimetry.
Although this method is more cost effective when com-
pared to the 3H-hypoxanthine method, it is an ELISA
method just like the HRP-2 method, which depends on
the availability of specific antibodies. The recently de-
veloped SYBR Green-1 fluorescence assay is based on
measuring the incorporation of the fluorescent SYBR
Green-1 dye into parasite DNA. This requires a single
step of DNA staining, it is less labour intensive and cost
effective compared to the other methods and it is more
amenable for HTS, which has become the gold stand-
ard in drug screening. This assay demonstrates the reli-
ability of a simple, rapid, inexpensive and easy to use
fluorescence-based method for drug susceptibility test-
ing of P. falciparum laboratory strains and clinical iso-
lates [45].
The exo-erythrocyte or liver stage is a very important
life cycle stage with respect to the eradication
programme. Recent progress has been made in the de-
velopment of HTS for identification of active com-
pounds against this stage of the parasite. There are
billions of parasites present in the human blood stage
infection, only a limited number of ookinetes, hypno-
zoites or early liver forms exists during transmission
and re-infection, hence the unlikely emergence of re-
sistance in the event of an intervention at these stages
[46]. Parasites injected with the mosquito’s saliva find
their way into the host liver, where they multiply
asexually as exo-erythrocytic forms (EEFs) during an
asymptomatic incubation period of about a week prior
to emerging into the blood stream. This initiates the
asexual erythrocytic cycle that is responsible for the
manifestation of malaria. Contrary to the limited life
span of some Plasmodium species, P. ovale and vivax
can persist within the liver as dormant hypnozoites for
several months. Their reactivation, which is usually
triggered by an unknown mechanism, could see rapidly
growing parasites re-populate the blood, thereby caus-
ing a pathology. Hence, the persistence of the hypno-
zoites represents formidable barrier to the eradication
process [47].
Amongst the blood stage forms of the parasite, a sub-
set, in response to cues that are not well understood,
can differentiate into male and female gametocytes in a
process that takes about 8–12 days in P. falciparum.
These parasites metabolize the host red cell hemoglobin
while progressing through five morphological distinct
stages that can be identified by light microscope [48].
These immature gametocytes can last in the host for up
to 55 days and mature gametocytes are the only form
that can survive in the mosquito midgut, mate, undergo
meiosis and give rise to next generation of parasites to
be transmitted to a new host [49]. The majority of com-
pounds active against the erythrocyte stage are inactive
against the liver stage and current first line artemisin-
based treatment regimens do not block transmission
[50]. A current focus of anti-malarial drug discovery is
to screen for small molecules and HMs that are active
against both liver and gametocytes in order to block
malaria transmission. The complex chemical diversity of
HMs is a sure source of such scaffolds in one system.
One of the major shortcomings of developing HTS as-
says to evaluate liver stage activity is that parasites can-
not be maintained in culture. A recently developed assay
that can be used to determine the efficacy of HMs with
known blood stage activity is the high content screening
(HCS) on P. yoelli infected hepatocytes. To detect likely
prophylactic activity, P. berghei or P. yoelli sporozoites
are seeded unto human hepatoma cells and the infection
is imaged [51] or detected enzymatically [52]. Alterna-
tively, using a medium throughput assay, the radical
potential of a test compound could be tested using the
hypnozoite-forming monkey model, P. cynolmolgi. P.
cynolmolgi sporozoites are seeded unto primary monkey
hepatocytes and HCS used to determine the ratio be-
tween large, rapidly developing schizonts and dormant
“small forms” (supposed hypnozoites). All parasites in-
cluding hypnozoites will be eliminated by radical cure
agents whereas prophylactic compounds will act on
growing schizonts [53].
Though assays are available for screening compounds
with transmission-blocking potential, these assays are
particularly difficult because the process of gametocyto-
genesis is not well understood. The first gametocyte
screen was conducted using alamar blue, an oxido-
reduction indicator that fluoresces and changes colour
in response to chemical reduction of growth medium
during metabolic activity of gametocytes [54]. Based on
this principle, other screens have been implemented
using lactate dehydrogenase [55]. During the 12 days it
takes for gametocytes to mature from the early to the
late (transmission) stage, they do not divide. Conse-
quently, methods based on the detection of inhibited
parasite proliferation are limited [37]. Alternative HTS
assay techniques to detect gametocyte death have been
developed, most of which use overall ATP hydrolysis to
measure viability. Hence the loss of this activity would
signify gametocyte death [54]. It is also possible to se-
lectively count parasites expressing a gametocyte-stage
specific GFP tag by flow cytometry [56]. However, most
of the assays only attempt to predict transmission-
blocking activity by measuring gametocyte death. Efforts
have been focused on more predictive assays aimed at
measuring viability at different stages, especially the later
stage [57]. Recently, Plouffe et al. [58] developed a HTS
and cost effective assay technique, the Saponin-Lysis
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Sexual Stage Assay (SaLSSA) for identifying small mol-
ecules with transmission-blocking capacity, which
clearly emphasizes substantial physiological difference
between asexual and sexual parasite and provides a tool
and starting point for the discovery and development of
transmission-blocking drugs.
One of the limitations of the relevance of HTS anti-
plasmodial efficacy assays is their inability to provide
information on some factors that influence the activity
of substances in vivo such as absorption, distribution,
metabolism, excretion and toxicity (ADME/T), which
describes the disposition of bioactive compounds in in
vivo systems. However, they still represent very import-
ant tools to identify and characterize active test sub-
stances [59] and this should be proceeded by
toxicological screening. This is very important for the
development of new drugs and for the extension of the
therapeutic potential of existing molecules and herbal
drugs, the first step of which is the screening on cell
lines or cytotoxicity.
Cell viability and cytotoxicity screening
Despite the growing market demand for herbal medi-
cines, there are still concerns associated with not only
their use, but their safety. Less than 10% of herbal prod-
ucts in the world market are truly standardized to
known active components and strict quality control
measures are not always diligently adhered to [60].
Therefore, cell viability and cytotoxicity assays are essen-
tial for drug screening and in vitro safety of anti-malarial
drug molecules and herbal products [61]. The import-
ance of including these assays anti-malarial plant profil-
ing, was emphasized by van Dyk et al. [62], when they
eliminated nine out of fifty-nine organic solvent extracts
of South African plants that exhibited anti-malarial ac-
tivity. A simple, rapid, sensitive, reliable, safe and cost-
effective measurement of cells viability is the ideal test
for in vitro cell proliferation and cytotoxicity and it
should not interfere with the compound to be tested.
These cell-based tests are performed to predict potential
toxicities, using cultured cells which may be normal or
transformed cells. The procedure normally involves
short term exposure of cultured cells to test compounds,
to detect the effects on basal or specialized cell function,
prior to performing safety studies on whole organisms.
It can also provide insight towards the carcinogenic or
genotoxic dispositions of the test substances. The ability
of a plant extract or test compound to inhibit cellular
growth and viability can be ascertained as an indication
of its toxicity, parameters of which include inhibition of
cell proliferation, cell viability markers (metabolic and
membrane), morphologic and intracellular differenti-
ation markers [63]. Some of the factors to be considered
when conducting these assays include cell culture
systems, cell type compatibility with solvent system used
for extraction and final concentration of dimethyl
sulphoxide (DMSO) to avoid toxicity [64]. DMSO is an
important aprotic solvent that can solubilize a wide var-
iety of otherwise poorly soluble polar and nonpolar mol-
ecules, due to its amphipathic nature. This, coupled with
its apparent low toxicity at concentrations <10%, has led
to its ubiquitous use and widespread application [65].
Another important factor to be considered is the selec-
tion of a wide range of high quality cell types for testing
including normal cells of primary origin and permanent
cell lines, due to the selective toxicity displayed by some
plant extracts. The advantage of using these cell lines in-
clude unlimited supply, no genetic variation, which aids
reproducibility and predictive power of an outcome, as
well as access to the collective knowledge gained from
global research conducted on the geno- and phenotype
of the cell line in question [66]. However, primary cell
cultures have an advantage over most perpetual cell lines
in that they are the closest in vitro representation of the
in vivo cell type under scrutiny. Hence, primary hepato-
cytes are considered the “gold standard” used for pre-
dictive toxicology because they are often employed with
the expectation that chemicals will affect or be affected
by an isolated cell in the same manner that would occur
in the whole organ [67].
Cell-based assays can be used to predict the mechan-
ism of toxicity depending on the endpoint that is
assessed; these include cell death/survival, adaptive/pre-
lethal mechanistic reactions, including mitochondrial
homeostasis, generation of reactive oxygen species
(ROS), lipid peroxidation, Ca2+ signaling, enzyme inhib-
ition and transporters endpoints [66].
Toxicokinetics
Toxicokinetics deals with the prediction of toxicity due
to pharmacokinetic disposition of an herb or pure com-
pound derived from it, as a result of genetics or potential
herb-drug interactions, especially given the increasing
use of anti-malarial plants for therapy in endemic coun-
tries. Therefore, toxicokinetics of antimalarial compo-
nents is of utmost important in evaluating the toxicity
and drug interaction of anti-malarial components.
Chung et al. [68] recently reported the toxicokinetics of
anti-malarial artesunate in rats. This assay involves the
use of human liver microsomal Cytochrome P450 iso-
forms and is aimed at the early identification of metabo-
lites which are known to cause toxicological modulation
in the cellular organization [69]. Cytochrome P450s are
heme-containing monooxygenases located in the small
intestine, liver and other tissues that play pivotal roles in
the detoxification and bioactivation of diverse xenobi-
otics [70]. Approximately 75% of all known drugs are
metabolized hepatically by mixed function oxidation
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reactions catalyzed by Cytochrome P450 isoforms
(CYP3A4, CYP2C9, CYP2C19, CYP1A2 and CYP2D6)
and they are highly subject to inhibition owing to their
broad specificity for structurally diverse substrates.
Modulation of Cytochrome P450 is of great significance
in drug biotransformation to active or inactive forms.
For drugs that are dependent on these enzymes for in-
activation via conjugation to chemical polar groups prior
to elimination, any herb that induces these enzymes
would lead to rapid inactivation and clearance of such
drugs. Herbs that inhibit enzyme activity will result to
high concentrations of the drug whose inactivation relies
on the enzyme activity. This could have serious implica-
tions for toxicity especially if the drug accumulated has
a narrow therapeutic window. Hence, clinically signifi-
cant drug-herb interactions can be observed when an
herb interacts with the metabolism of a co-administered
drug and either reduces its efficacy due to increased for-
mation of an active metabolite or increases its toxicity
due to reduced metabolite elimination [71]. This clinic-
ally significant effects can be predicted by analyzing in
vitro metabolic data and correlating it with metabolic
disposition of a test substance in vivo [72].
In vitro therapeutic index
The in vitro therapeutic index (TI), otherwise known as
the selectivity index (SI) of test compounds in malaria
drug discovery research is a measure of the amount of
the therapeutic agent that causes toxicity relative to that
which causes the therapeutic effect (antiplasmodial ac-
tivity). That is, cytotoxicity (CC50)/antiplasmodial activ-
ity (EC50 or IC50) [73, 74] and represents the therapeutic
safety, which is the basis for selectivity of anti-malarial
components for in vivo validation. In a recent study,
Lima et al. [75] used SI values as a basis to select three
among sixty-nine Amazonian plant extracts, for further
in vivo studies. The higher the TI values for the herbal
extracts or compounds derived from them, the more
therapeutically safe they are considered, indicating that
smaller quantities of such products will be needed to
achieve high clinical efficacy with increased tolerability
and safety [76]. It should be noted that although the
minimum TI “cut-off” value for prioritizing samples is
usually considered at SI > 4 [77], it is somewhat subject-
ive because of the difference in susceptibilities of various
cell lines and parasite strains to test compounds [78].
The effectiveness of any plant extract is dependent
upon a favourable therapeutic ratio; that is the drug
must kill or inhibit the parasite but have little or no tox-
icity to the host. The selectivity of a plant to inhibit the
growth of a parasite and yet be less toxic to the host de-
pends on differences in biochemistry between the para-
site and the host. Such a plant could operate on a
biochemical target in the parasite that is either absent or
significantly different in the host [79].
Characterization of the interactions between
herbal extracts
Despite the use of herb-herb combinations for therapy
over the past millennia, scientific evidence of their
therapeutic benefits is still lacking. With the increasing
interest shifting from the “one-drug-one-target” to
“multi-target” or combination therapy for optimum
benefits, there is momentum to explore new knowledge
by tapping the past empirical experiences of herb-herb
combinations. Systematic screening of combinations of
some approved drugs with natural products in certain
disease models has started only recently [80] but the
potential of combining anti-malarial drugs and/or herbs
is not yet systematically explored. There is therefore
the need to characterize the interactions between anti-
malarial herbal extracts and/or bioactive compounds
derived from them to understand the multi-target con-
cept in phytotherapy. These combinations may exhibit
synergy at some doses, while resulting in additivity or
antagonism at others. Combination dose response in in
vitro antiplasmodial assays over combined dose ranges
provide critical information on how different com-
pounds act together to affect different Plasmodium in-
fection outcomes [81]. The method used in combining
these plant extracts is known as the fixed ratio method
[59] and a modified method of combining them at equi-
potencies and variable potencies in antiplasmodial as-
says have been reported to give reproducible results
[82, 83].
Briefly, active solvent extracts (say A and B) are com-
bined in pairs at equipotency (5EC50A:5EC50B) or in
variable potency (5EC50A:0EC50B to 0EC50A:5EC50B) ra-
tios and each combination screened on resistant strains
of Plasmodium falciparum, (such as Dd2) in an appro-
priate HTS assay set-up, using anti-malarial drug combi-
nations of chloroquine/chloroquine and chloroquine/
artemisinin as drug-drug interaction controls [84].
Measurements to quantify these interactions include
mathematical and graphical models [85–87]. The math-
ematical model requires plotting the logarithm of the
extract combination concentrations against activity (for
example represented by the fluorescence reading) to
obtain a nonlinear regression curve-fitting and a vari-
able slope sigmoidal dose–response curve, from which
inhibitory coefficients (IC50) of each extract in combin-
ation are determined. These are in turn used to calcu-
late fractional inhibitory concentrations (FIC50A =
IC50A in combination/IC50A alone) and eventually
combination indices (CI = FIC50A + FIC50B), recognized
as the standard measure of combination effect that
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indicates a greater (synergistic, CI < 1), lesser (antagon-
istic, CI > 1) or similar (CI = 1) effect than the expected
additive effect.
Graphical models require the use of the previously cal-
culated FIC50s of each extract in combination for each
of the variable potency combination ratios to plot iso-
boles. These are plots with the line of additivity running
from point (0,1) of the vertical axis to point (1,0) of the
horizontal axis. Analysis of these isoboles, known as iso-
bologram analysis, will enable the prediction of the type
of interaction that exists between the plant extracts.
Plant extracts in combination may produce effects that
are greater than or less than their individual effects. The
basis for predicting their effects in combination is based
on relative potencies or dose equivalence. Therefore, a
plot of the FIC50s of plant extracts with a constant rela-
tive potency, will produce linear additive isoboles (curves
of constant effect), whereas varying potency ratios pro-
duce nonlinear additive isoboles.
Synergy or antagonism will be revealed when the plot-
ted FIC50 values is situated below or above the line of
additivity, respectively. An illustration of these is shown
in Fig. 2, in a study carried out by Tarkang et al. [84].
Based on Chinese herbal medicine, phyto-preparations
are formulated deliberately according to the following
basic modes of herb-herb interactions; reinforcement,
potentiation, restrain, detoxification, counteraction and
toxicity. The rational of this principle suggests four
mechanisms: (i) synergistic multi-target effects on en-
zymes, substrates, metabolites, receptors, ion channels,
transport proteins and antibodies (ii) pharmacokinetic or
physicochemical effects based on improved solubility, re-
sorption rate and enhanced bioavailability (iii) antagonis-
tic interactions with resistance mechanisms of pathogens
such as P. falciparum (iv) elimination or neutralization
of adverse effects caused by other substances present in
the mixture [80, 88]. Overall, the aim remains always an
effective therapy with less adverse effects.
Besides quality assurance, the proof of efficacy of
phyto-preparations and the determination of their mode
of action remain permanent issues for an evidence-based
approach. The “omics” technologies (genomics, proteo-
mics and metabolomics) are high throughput platforms
that can provide us with these possibilities, especially for
the identification of the multiple targets of identified
plant constituents [88].
These in vitro analyses of the effects of polyherbals
gives us an idea of effects to expect in in vivo and clin-
ical studies. Before translating this data further in the
drug discovery process, the following considerations
must be made during these combination analysis: (i) an
appropriate use of concepts and methods (ii) a standard
reference analysis framework for characterization (iii)
adaptation of the analysis to each step of the research
and development process (iv) optimization of dose ratio
(v) interpretation of combinations effects guided by
Fig. 2 Isobolograms of the in vitro interactions between differential solvent extracts of a polyherbal product at variable potency ratios (a)-Additive
interaction: Chloroquine/chloroquine combination (b)-Antagonistic interaction: Chloroquine/Artemisinin combination (c)-Synergistic interaction:
MiB/Pg aqueous extracts combination (d)-Synergistic and antagonistic interactions: MiB/Cs aqueous extracts at different potency
combinations [79]
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rigorous methodology (vi) combining more than two
herbs as is usually the case with polyherbals [89].
Plant metabolomics
Metabolomics is increasingly playing a vital role in nat-
ural products drug discovery process. It aims at the
comprehensive qualitative and quantitative analysis of
the plant metabolome which consists of both primary
and secondary metabolites, the end products of the cel-
lular regulatory processes. This approach is based on
the unbiased acquisition of MS and NMR data from
specially prepared samples [13]. Application of state-of-
the-art mining on this data leads to sample classifica-
tion and identification of relevant biomarkers, which is
very vital in lead discovery and understanding the
multi-target mode of action in malaria phytotherapy.
However, this method requires specific extraction (as
discussed earlier) and sample preparation techniques.
Since the aim is to comprehensively profile the largest
possible array of low molecular weight metabolites in a
given biological sample, techniques such as multiple-
phase solvent systems [31] coupled to accelerated ex-
traction processes such as microwave [90], ultrasonic
[91], pressurized or accelerated liquid [92] can be ap-
plied to drastically reduce extraction times. Sample
preparation usually involves the use of quality buffer
and deuterated solvents that will minimize the chemical
shift due to pH of the sample solution and result in
good quality spectra [93].
There are various hyphenated chromatographic tech-
niques for data acquisition such as the LC-MS, gas
chromatography (GC)-MS and capillary electrophoresis
(CE)-MS, as well as direct spectroscopic methods such
as NMR and direct injection mass spectroscopy
(DIMS). However, LC-MS is the most widely used tech-
nology in phytotherapeutic drug discovery due to its
ability to detect and separate a diverse range of mole-
cules with high sensitivity. When coupled to the NMR,
it is even more versatile. The successful combination
and application of these analytical tools, data mining
and processing, in combination with bioassay profiling
methods serve an important role in metabolomics for
the purpose of dereplication in natural products-based
drug discovery [17, 94].
HPLC-based anti-malarial profiling
HPLC-based anti-malarial profiling is a highly versatile
strategy to accelerate deconvolution of active herbal ex-
tracts. The principle of this approach consists of separat-
ing bioactive components of herbal extracts by analytical
and semi-preparative HPLC. The first step which is a
microfractionation can be performed with the bioactive
sample from the generated plant library, since very little
quantities of extract can be used, thereby avoiding the
time-consuming recollection and extraction of samples,
which at times is non-reproducible. The generated ultra-
violet and MS data are recorded on-line and in combin-
ation with data searches, can be used for early
dereplication and tentative identification of bioactive
compounds. In parallel, fractions can be collected into
microplates via a T-split of the column effluent, dried
and re-dissolved in suitable solvent [95]. These will then
then be assayed in vitro for their activities blood and
exo-erythrocytic stage malaria parasites, using appropri-
ate HTS assay set-ups as discussed earlier. In order to
assess the full bioactivities of each extract, they will also
be assayed for other activities relevant in the pathogen-
esis of malaria, such as antioxidant [96, 97], anti-
inflammatory, antinociceptive and antipyretic [98, 99].
By matching the chromatogram and the activity profile,
active peaks can be identified.
NMR data for eluted fractions and peaks are recorded
off-line using microprobe NMR technology. The col-
lected HPLC peaks can be processed in parallel and an
NMR autosampler allows unattended measurement of
1H NMR spectra which serves as a basis for more
advanced 1D and 2D analysis. If the need arises, subse-
quent HPLC preparative sample purification can be
performed using a peak-guided strategy, since the chro-
matographic conditions can be easily transposed.
For a successful application of this methodology, the
aspects that need to be considered include the choice of
column diameter depending on the miniaturization (ana-
lytical or semi-preparative) and sensitivity of the bio-
assay, sample injection and column flow rates, choice of
solvents for bioassays [94].
In the past decade, the application of HPLC-based
anti-malarial profiling in targeted and untargeted meta-
bolomics, for the analysis of plant extracts and HMs has
been well established. Studies highlighting this potential
include the quality control of various Artemisia species
[100], correlation of antiplasmodial activities with the
plants’ metabolome and efficient tracking of metabolites
[101, 102]. In addition to the efficient tracking of bio-
active metabolites, activity profiles can be defined, which
are vital for prioritization and chemical analyses. With
this information, isolation capacities can be dedicated to
bioactive portions in view of facilitating the formulation
of standardized and effective phytomedicines for down-
stream clinical development. In a recent study, Suberu
et al. [103] reported the use of multivariate analysis of
generated metabolomics data, to identify the association
and correlation of the metabolites of artemisinin and re-
lated compounds in extracts of varieties of Artemisia
annua. This study was aimed at determining the effects
of different growth conditions, species’ origin and identi-
fication of adulterants. In another study, Allman et al.
[104] reported that the metabolomics profiling of the
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malaria box revealed several major classes of metabolic
disruption, which allows for the prediction of the mode-
of-action for many of the Malaria Box compounds [104].
These results can influence the selection of appropriate
drug combinations that simultaneously target multiple
metabolic pathways, in future combination therapies,
aimed of eliminating malaria and forestalling the expan-
sion of drug-resistant parasites in the field.
Metabolomics has also been applied for the analysis of
other biological systems such as the serum and urine of
Plasmodium-infected hosts, in order to unveil host-
pathogen interactions [105, 106]. Though still in its
infancy, it enables the unveiling of novel aspects of parasite
and vector biology. Furthermore, it provides insights into
the biochemistry of the host, the nature of host-parasite
interactions during infection, and makes it feasible for us
to discover species-specific biomarkers that might correl-
ate with various clinical manifestations of malaria.
Therefore, the metabolomics workflow and anti-
malarial metabolomics profiling approach provide the
malaria community with data that can be used to help
prioritize the next generation of potent anti-malarial
drugs for future testing in clinical trials.
Armed with the activity profile of the HMs, the next
vital step is to validate these activities in animal pharma-
cology, as well as confirm the safety profile.
Animal pharmacology and safety studies
In accordance with the reverse pharmacology or target-
directed approach, test substances identified with good in
vitro antiplasmodial activity need to be tested in vivo in
suitable animal models that can provide basic pharmaco-
logical and toxicological data prior to subsequent human
clinical trials [59]. Despite the fact that these in vivo assays
do not necessarily predict the outcomes of clinical trials in
humans because the pathogen models in animals are dif-
ferent from the human pathogens, animal models remain
very vital in malaria phytotherapy. However, due to the
reasonably high homology and similarity between mam-
malian genomes and physiology, and to the relatively short
reproductive cycle, mouse and rat models are the most
used for assessment of antiplasmodial activity of plant ex-
tracts and products derived from them [107]. Therefore,
these animal models remain crucial for malaria drug
evaluation and validation because they provide an inte-
grated response encompassing efficacy, bioavailability, side
effects and toxicity (ADME/T) of test substances in a
whole organism and can be used for pharmacokinetic and
safety studies that are pre-requisite for human clinical tri-
als [108–110].
Toxicity testing
While cell-based assays may be predictive of potential
toxicity, use of the whole animal measures the critical
toxicity of the test substance, to determine signs of tox-
icity as a result of gradual increase in the dose of the test
substance. Many research groups are resorting to plants
as a major source of new anti-malarial chemotherapeutic
agents because of the extensive use of these plants for
malaria therapy in African Traditional Medicine. Their
use, however, does not take into consideration their
safety [111]. It is therefore imperative to establish the
pre-clinical safety profile of plants and their components
that exhibit good anti-malarial activity in animal models.
Standard guidelines have been established internationally
for the care and use of animals in toxicity studies [112].
These guidelines take care of the preparation and
administration of test substances, animal welfare consid-
erations, choice of animals and regulatory requirements.
The toxicity tests that are usually carried out include
acute, sub-acute/sub-chronic and chronic toxicities.
Exposure routes may be by oral gavage, inhalation, der-
mal, intraperitoneal or intramuscular, depending on the
intended use and/or route of administration.
Acute toxicity testing measures relative toxicological
response of an experimental organism to a single or
brief exposure to a test substance [112]. This test is
used to calculate lethal dose (LD50) [113] and observa-
tion usually lasts for fourteen days. Sub-acute (28–30
days) and sub-chronic (60–90 days) are repeated-dose
daily exposure to test substances with a view of evaluat-
ing the effects on the physiological, biochemical and
histopathological parameters of the organ systems of
test animals. Chronic toxicity testing which is similar to
sub-chronic involves the exposure of test animals over
a period of six to twenty-four months or more, to re-
veal the effects on organ systems [114]. In addition,
specialized tests may follow to reveal specific toxicities,
such as reproductive, developmental, eye, skin irritancy,
neuro- and geno- toxicities [115].
In vivo antiplasmodial assays
In vivo tests are the oldest approach in the assessment
of therapeutic responses and have enabled determination
of the thresholds of treatment failure that are crucial for
adjusting anti-malarial drug policies [116]. Test sub-
stances effective in in vitro tests are taken up for in vivo
evaluation. Since Plasmodium species that cause hu-
man malaria are essentially unable to infect non pri-
mate animal models, in vivo evaluation of anti-malarial
compounds begins with the use of rodent malaria para-
sites. These include Plasmodium berghei, P. yoelii, P.
chabaudi, P. vinckei (blood and gametocyte stages
screening) and P. cynomolgi (liver stage screening). In
vivo models are usually employed in anti-malarial stud-
ies because they take into account the possible prodrug
effect and probable involvement of the immune system
in eradication of the pathogen [117]. These in vivo
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methods have been validated through the identification
of standard drugs like mefloquine and artemisinin [118,
119] and thus remain a standard in herbal medicines
drug discovery. They can be classified into primary,
secondary and tertiary biological assessments [120]. In
all methods, determination of percent inhibition of
parasitemia is the most reliable parameter. A mean
parasitemia level ≤ 90% to that of the vehicle treated an-
imals (mock-treated control) usually indicates that the
test compound is active [121].
The most widely used primary biological test is the P.
berghei 4-Day suppressive test [122], which requires the
infection of test mice with P. berghei, ANKA strain on
day 0. 3 h post-infection and on day 1–3, the mice are
treated with the test substance while using chloroquine
and artemisinin as standards. On day four, blood smears
from all groups of animals are prepared and stained with
giemsa stain. Parasitaemia is determined from day 4 to 6
and substances identified as active are further subjected
through several secondary biological assessments such
as dose ranging, curative and prophylactic tests.
The dose ranging test requires a minimum of four dif-
ferent doses of the test substance (the “dose ranging, full
4-day test”). ED50 and ED90 values are calculated by
plotting the log dose against probit activity and reflect
the concentrations at which 50% and 90% of suppression
of parasitaemia is achieved. This test also leads to infor-
mation about the relative potency compared to an ap-
propriate standard drug [121].
The Curative test, otherwise known as the Rane’s test,
involves the daily administration of the test substance to
mice or rats, 72h (D3) post established infection, for a
period of five days. Parameters followed up are measure-
ment of the reduction in blood stage parasitemia and
improved survival of test animals [123]. However, in the
liver stage screening, the radical cure potential of a test
compound is tested using the hypnozoite-forming mon-
key model. Monkeys are infected with P. cynomolgi spo-
rozoites followed by treatment with a compound that
eliminates all blood stage parasites, followed by the test
compound. The monkeys are then monitored over sev-
eral months to measure reductions in the frequency of
hypnozoite-caused relapses as an evaluation the poten-
tial of the test compound for radical cure [124]. The
transmission-blocking activity of the test compound
could also be assayed by taking advantage of the ability
of gametocytes to infect mosquitoes; this can be mea-
sured by using standard membrane feeding assay, using
P. falciparum [125], or by direct feeding of an infected
mouse [126]. After feeding, the number of oocysts per
mosquito midgut are counted to determine the efficacy
of the test compound.
For the prophylactic test, substances with a thera-
peutic lead are tested for prophylactic activity by
administering them for three days prior to infection
and smears continually examined daily for three days,
to assess suppression of blood stage parasitaemia and
improved survival [127].
Tertiary biological assessments are used to monitor
cross resistance and in vivo generation of drug resist-
ance. Cross resistance monitoring employs the 4-day
suppressive test in order to determine whether the same
ED50 and ED90 values are observed in drug-resistant
strains of rodent malaria when compared to P. berghei
ANKA infection [121]. To determine the potential of
parasites to develop resistance to a new compound in
vivo, the 2% relapse method is the most widely used for
most classes of compounds [128]. This entails adminis-
tering a dose of the test substance that when given 1 h
before infection, delays the development of 2% parasit-
aemia until about 7–10 days post-infection. When this
parasitaemia is attained, the procedure is repeated and
the time to reach 2% parasitaemia is monitored on a
daily basis. The degree of resistance is expressed as a re-
duction in “delay time to 2%”. This method can be ex-
tended to demonstrate the stability of resistance
following the removal of drug pressure and to select a
partner compound that can slow the rate of develop-
ment of resistance.
Pharmacokinetics
There is evidence that the crude extracts of whole plants
or mixtures thereof, which are widely used for malaria
therapy, exhibit greater in vitro and/or in vivo antiplas-
modial activities than isolated compounds from them, at
equivalent doses. This might be as a result of synergistic
interactions between their components which result in
an overall positive anti-malarial effect [129]. Pharmaco-
kinetics (PK) of these anti-malarial plants remains a
major problem due to the number of plant-derived mol-
ecules that are typically present in them. This presents a
substantial challenge to chemical and pharmacological
evaluation, in addition to the wide concentration range
of these molecules. Furthermore, the dynamic nature of
the type of chemical interactions between their bioactive
components and endogenous molecules have a great
influence on their PK, and consequently on treatment
outcomes in humans [130]. Moreover, monitoring of
chemical profiles have been made more complicated due
to their complex biological matrices and the lack of au-
thenticated standards. The evolutionary considerations
in interdisciplinary expertise involving ‘omics’ technolo-
gies, pharmacology, biochemistry, bioinformatics and
systems modeling, offers new opportunities [94]. How-
ever, understanding their metabolic fate is a critical step
toward the development of next generation of combina-
torial drugs, which will maximize the synergistic and/or
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antagonistic effects of bioactive components and
minimize their undesirable metabolic side effects [131].
The advent of comprehensive profiling technologies
offers tremendous new opportunities for understanding
multicomponent PK. Phytochemical profiling and meta-
bolomics, coupled to multivariate statistical tools to gen-
erate multiparametric assessments, enable us to create a
concentration-time profile of these anti-malarial plants,
in a process known as a “Poly-PK” approach. This ap-
proach uses the integrated diversity of chemical compos-
ition and metabolomics profiling strategy coupled to
multivariate statistical to simultaneously monitor the
complex effects on the metabolic pathways of the mam-
malian system [131, 132]. When anti-malaria plant ex-
tracts enter mammalian bodies, the following metabolite
profile changes occur over time: (i) Plant-derived com-
pounds are absorbed into the circulation (ii) new metab-
olites are generated by the chemical transformation of
these compounds by hepatic enzymes and gut microbes
(iii) endogenous metabolites are altered in response to
their intervention.
Certain PK variables such as plasma and urine concen-
tration can be collected over time of treatment, and char-
acterized using UHPLC-MS, while parameters such as
area under the curve and the elimination half-life (t1/2)
can be generated using PK modeling software [133]. Ana-
lysis of the various metabolomes of treated and non-
treated mammals, can generate a correlation between the
dynamic concentration profiles of bioactive components
and the human metabolic response profile. Therefore, this
approach of simultaneously monitoring the PK behaviours
of multiple phytochemicals in vivo can lead to the direct
elucidation of the pharmacological and molecular mecha-
nisms underlying anti-malarial plants. This approach
therefore reveals the interrelationship between xenobiotics
and endobiotics, as well as the metabolic impact of these
plants, using pharmacodynamics (PD) endpoints, to pro-
vide insight into the mechanisms of action and advance
novel therapeutic development.
Conclusion
Drawing from the prolonged history of phytotherapy for
the clinical management of malaria, there is evidence
that plant extracts exert superior effects compared to
isolated phytochemicals. This is as a result of the multi-
target effects of their secondary metabolites. Therefore,
the success rate of developing a new drug from herbal
medicinal preparations should, in theory, be higher than
that from chemical synthesis. By setting quality stan-
dards to this reductionist interdisciplinary approach, po-
tential biomarkers as well as the cellular and molecular
modes of action would be unraveled. This endeavor will
not only facilitate a fast and convenient discovery of effi-
cient and standardized improved traditional medicines,
but eventually lead discovery for downstream chemical
analyses and prioritization. Therefore, this approach
should be an asset in natural products-based drug dis-
covery, which might shift the paradigm from the capital
intensive “one-drug-to-fit-all” to the new “less invest-
ment, more drugs” model. It is believed that the former
will be unsustainable in the short run, hence the need
for new approaches towards the latter. Another major
asset of this approach is the ethnopharmacological infor-
mation providing hints for therapeutically effective
plants and miniaturization, thereby reducing random
and indiscriminate harvest of plants and promoting the
preservation of biodiversity.
Therefore, by unifying a complete state-of-the-art re-
ductionist and holistic techniques, the application of the
multi-target phytotherapeutic concept holds great prom-
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